Urapidil Stragen 30 mg prolonged-release capsule, hard.
Urapidil Stragen 60 mg prolonged-release capsule, hard.
Urapidil Stragen 90 mg prolonged-release capsule, hard.
Pharmaceutical Form |
---|
Prolonged-release capsule, hard. Urapidil Stragen 30 mg: capsule N°4 with a translucent dark yellow body and an opaque white cap filled with small spherical beige pellets. Urapidil Stragen 60 mg: capsule N°2 with a translucent light blue body and an opaque white cap filled with small spherical beige pellets. Urapidil Stragen 90 mg: capsule N°1 with a translucent red body and an opaque white cap filled with small spherical beige pellets. |
Each Urapidil Stragen 30 mg prolonged-release capsule, hard contains 30 mg urapidil.
Each Urapidil Stragen 60 mg prolonged-release capsule, hard contains 60 mg urapidil.
Each Urapidil Stragen 90 mg prolonged-release capsule, hard contains 90 mg urapidil.
Excipients with known effect:
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Urapidil |
Urapidil is a α1-adrenoceptor antagonist and 5-HT1A receptor agonist and consequently inhibits the vasoconstrictor effect of catecholamines. It interacts with peripheral α1-adrenoceptors and central 5-HT1A receptors to produce vasodilation without sympathetic activation. |
List of Excipients |
---|
Capsule contents: Sugar spheres (sucrose, maize starch) 30 mg capsule shells: Gelatin 60 mg capsule shells: Gelatin 90 mg capsule shells: Gelatin |
Polypropylene bottle with polyethylene desiccant cap.
Box of 30, 50, 90 and 100 prolonged-release capsule, hard.
Not all pack size may be marketed.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.